Cytiva has acquired a new chromatography resins manufacturing site in the United States as part of its $1.5 billion capacity expansion investment. Cytiva announced on July 13, 2022 that it had ...

Biopharma’s ongoing quest to develop COVID-19 drugs and vaccines, plus growing industry demand for producing various types of new therapies, are fueling the $1.5-billion expansion of manufacturing ...

Cytiva says it will spend $600 million to build its first chromatography resin plant outside Sweden. The company, owned by Danaher, has acquired a facility in Muskegon, Michigan, that it will retrofit ...

Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Biotherapeutic Manufacturing Chromatography Market - A Global and Regional Analysis: Focus on Product Type, Type, Matrix Type, Application, End User, and ...

Cytiva introduced a new technology called Protein Select that the company says is designed to streamline and accelerate recombinant protein purification. The self-cleaving traceless tag and ...

Cytiva, backed by a $1.5 billion investment from its parent company, the Danaher Group, continued its expansion tear with the acquisition of CEVEC Pharmaceuticals. CEVEC, which is based in Cologne, ...

Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Global Chromatography Software Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global ...

Cytiva, the former GE Healthcare Life Sciences, as well as Pall Corp., which specializes in high-tech filtration, separation and purification, announced on Tuesday a plan to invest $1.5 billion ...

The biopharma industry is looking at continuous chromatography for sensitive molecules. Continuous processes continue to advance in bioprocessing. In downstream processing, continuous chromatography ...

“[O]n the facts here, binding is not disputed. Thus, if the ligand binds, the ligand is capable of binding.” – Federal Circuit On Wednesday, December 4, the U.S. Court of Appeals for the Federal ...